Medtronic's neurostim device approved in US
This article was originally published in Clinica
Executive Summary
Medtronic has another neurostimulation device to offer the 75 million patients with difficult-to-treat chronic pain. The US FDA last week approved the company's RestorePrime device, the first non-rechargeable neurostimulator with up to 32 programming options and the coverage size of a rechargeable unit.